Javascript must be enabled for this website to work.

#script { display:none; } #noScript{ width: 350px; height: 175px; text-align: center; background: white; padding: 35px; display: block; margin-top: -87px; top: 50%; position: absolute; border-bottom: 1px solid #c2c2c2; border-left: 1px solid #e6e6e6; border-right: 1px solid #e6e6e6; border-radius: 5px; -webkit-border-radius: 5px; -moz-border-radius: 5px; margin-left: 50%; left: -175px; } #noScript img{width:100%;} body{background:#f7f7f7;}

Updated COPD-X guide reflects stronger evidence for triple therapy

As-needed ICS now available on PBS for mild asthma

Osimertinib could be new standard of care for EGFRm NSCLC

CF patients with liver disease at high risk of bone loss and diabetes

Pulmonary complications and mortality high in surgical patients with COVID-19

Asthma

Stop spirometry and respiratory therapies: TSANZ

By Michael Woodhead

31 Mar 2020

Lung function testing and the use of respiratory therapies such as nebulisers should be stopped in all but medically essential cases because of the risk of COVID19 transmission, the Thoracic Society of Australia and New Zealand (TSANZ) has advised. There is potential for spread of airborne droplets from an infected person undergoing lung function testing ...

Already a member?

Forgot my password

Not a member yet?

Join now for free, independent news relevant to your specialty. the limbic is intended for practicing health care professionals only.

Title: *

First name: *

Last name: *

Country: *

Email: *

Password: *

Password must contain at least 8 characters including 1 letter and 1 number.

AHPRA Number: * Find my AHPRA number

What's your primary area of interest? *

The limbic's weekly newsletter is a round up of key news highlights that's relevant to your specialty. The newsletter may contain advertising and educational or promotional material from carefully selected industry partners including pharmaceutical companies, government and not-for-profit organisations.

You will not receive advertisers only emails and your details will not be shared with any other party.

I would like to receive the limbic newsletter *

I have read and agree to the limbic Terms and Conditions & Privacy Policy *

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cancel

Top Stories